ERBB2 and breast carcinoma: Intriguingly, METTL3 depletion has also been found to activate the CDKN1A/EMT pathway and m6A-BAX/caspase-9/-3/-8 cascade, thereby promoting proliferation, migration, and drug resistance in hormone receptor-positive HER2-negative breast cancer (HR+HER2-BC) (196).